The visions of the founders of DiaSys are just as valid today as they were in the past: improving laboratory diagnostics while keeping the environmental impact of the required products as low as possible.
The initial years were characterized by the development of liquid-stable reagents for the determination of enzymes and substrates, which quickly replaced the lyophilisate reagents that had been available on the market until then. Until the introduction of the first immunoturbidimetric reagent in 1995, the reagent portfolio for clinical chemistry was continuously expanded and an international sales structure was built up at the same time. In addition, DiaSys expanded its product range in 1998 with quality control materials such as multi-calibrators, multi-controls and parameter-specific calibrators and controls.
With the introduction of a semi-automated laboratory analyzer in 2000, DiaSys took its first step into a new business field as a system provider, which was expanded the very next year by the introduction of systems for point-of-care diagnostics. Between 2000 and 2009, DiaSys acquired international stakes in several companies, won and founded new distributors, took over companies or business units and continuously expanded its reagent portfolio by introducing e.g. CRP U-hs FS and oneHbA1c FS.
Starting in 2009, further steps were taken to become a system provider by introducing respons®910 and respons®920 as an innovative system family for small and medium-sized laboratories and by strengthening the area of point-of-care diagnostics with the InnovaStar®. In 2010, DiaSys also introduced the BioMajesty JCA-BM6010/C for laboratories with high sample throughput.
Efforts to grow DiaSys and its global partnerships have been ongoing. Thus, in the years between 2012 and 2016, investments in the Asian region were made, followed by the establishment of DiaSys India and DiaSys USA. With the acquisition of Diaserve in 2016, a specialist in manufacturing of calibrators and controls was integrated into the DiaSys Group.
In 2019, the respons® system family was expanded by the new respons®940, which is used in medium to large laboratories. At the same time, the new enzymatic HbA1c net FS, the modern way of HbA1c determination, was launched.
Before the impact of the Corona pandemic reached DiaSys in 2020, the introduction of the highly accurate Procalcitonin FS test for sepsis diagnosis enriched the group of particle-enhanced immunoturbidimetric tests. Due to the current occasion in 2021, rapid tests for Corona diagnostics were introduced as well as the SARS-CoV-2 UTAB FS test for the quantitative determination of SARS-CoV-2 total antibodies, which can be used universally on many analyzer platforms.
What's next? DiaSys turns 30 years young and still has many surprises in store!